📰 Practice Guidelines News
Page 34 - Practice Guidelines News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Practice Guidelines. Real-time updates on events, politics, business and more.
October 19, 2022
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—has...
October 17, 2022
/PRNewswire/ -- New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA...
October 10, 2022
The National Comprehensive Cancer Network's Distress Thermometer helps people with cancer worldwide receive better care by empowering discussion and recommending best practices for managing
October 10, 2022
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced an updated NCCN Distress Thermometer, available in more than 70 languages,...
October 6, 2022
The development of the boys and men practice guidelines was undertaken by a large group of scholars and clinicians who have devoted their lives to the psychological study of men and masculinity
October 6, 2022
Multi-site study shows personalized ctDNA analysis is highly prognostic of recurrence-free survival and outperforms CA-125 in identifying patients at high risk of recurrence AUSTIN, Texas, Oct. 6,... | October 6, 2022
September 27, 2022
/PRNewswire/ -- For the first time in three years, the National Comprehensive Cancer Network® (NCCN®) is hosting its yearly blood cancer congress in person....
September 22, 2022
/PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—released updated recommendations from the NCCN...
September 21, 2022
PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Histology findings from paired liver biopsies showed
September 16, 2022
Access a treatment regimen chart with information about therapies for pancreatic adenocarcinoma such as systemic chemotherapy and clinical trial options.